ERBIN and SCN4A

Data Source:
BioGRID (unspecified method)

		ERBIN	SCN4A
Description		erbb2 interacting protein	sodium voltage-gated channel alpha subunit 4
Image
GO Annotations	Cellular Component	Basement Membrane Nucleus Cytoplasm Plasma Membrane Basal Plasma Membrane Basolateral Plasma Membrane Nuclear Speck Cell Junction Hemidesmosome Nuclear Membrane Postsynapse Glutamatergic Synapse	Voltage-gated Sodium Channel Complex Integral Component Of Plasma Membrane Axon
	Molecular Function	Signaling Receptor Binding ErbB-2 Class Receptor Binding Structural Constituent Of Cytoskeleton Protein Binding	Voltage-gated Ion Channel Activity Voltage-gated Sodium Channel Activity Protein Binding
	Biological Process	Protein Targeting Cell Adhesion Signal Transduction Epidermal Growth Factor Receptor Signaling Pathway Integrin-mediated Signaling Pathway Negative Regulation Of NF-kappaB Transcription Factor Activity Response To Muramyl Dipeptide Response To Lipopolysaccharide ERBB2 Signaling Pathway Intermediate Filament Cytoskeleton Organization Basal Protein Localization Establishment Or Maintenance Of Epithelial Cell Apical/basal Polarity Positive Regulation Of Ras Protein Signal Transduction Negative Regulation Of Nucleotide-binding Oligomerization Domain Containing 2 Signaling Pathway Cellular Response To Tumor Necrosis Factor Negative Regulation Of Monocyte Chemotactic Protein-1 Production Regulation Of Postsynaptic Membrane Neurotransmitter Receptor Levels	Sodium Ion Transport Muscle Contraction Neuronal Action Potential Regulation Of Ion Transmembrane Transport Sodium Ion Transmembrane Transport Membrane Depolarization During Action Potential Regulation Of Skeletal Muscle Contraction By Action Potential
Pathways		Signaling by ERBB2 Downregulation of ERBB2 signaling Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants	Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation
Drugs			Ranolazine Topiramate Lidocaine Valproic acid Lamotrigine Carbamazepine Oxcarbazepine Propofol Cocaine Zonisamide Promethazine Flecainide Brivaracetam Tetracaine Amylocaine Propoxycaine Pramocaine Pentoxyverine Parachlorophenol Dichlorobenzyl alcohol Bioallethrin Fish oil
Diseases			Hyperkalemic periodic paralysis (HyperPP) Potassium-aggravated myotonias (PAMs), including: Myotonia fluctuans; Myotonia permanens; Acetazolamide responsive myotonia Hypokalemic periodic paralysis (HypoPP) Paramyotonia congenita (PMC) Congenital myasthenic syndrome
GWAS			Height ( 28552196 31562340)
Interacting Genes		66 interacting genes: ABCA1 ABCC4 ABR ACTN1 ACTN2 ACVR2A ACVR2B AGTR2 APC ARHGEF7 ARVCF ATP2B1 ATP2B2 ATP2B4 BANF1 CASK CDH1 CHUK COPB1 CTNNB1 CTNND1 CTNND2 CTSG DLG4 DST ERBB2 FOXO3 GRIN2B GRIN2C GUCY1A2 ITGB4 KCNA4 KCNA5 LAMB1 LMO1 LMO2 LRRC1 MAP4 MAPK12 MCC MEF2A MPP1 MPP2 MPP3 MUSK NOD2 NR2E1 PICK1 PKP4 RAF1 RBX1 RNF7 RPS6KA1 SCN4A SHOC2 SLC5A5 SLC5A6 SLC6A12 SMAD1 SMAD2 SMAD3 SMAD4 SMAD7 STAT3 VIPR2 ZFYVE9	10 interacting genes: CALM1 DLG1 DLG2 DLG3 ERBIN PATJ SLC9A3R1 SNTA1 SNTB1 SNTB2
Entrez ID		55914	6329
HPRD ID		06090	04912
Ensembl ID		ENSG00000112851	ENSG00000007314
Uniprot IDs		Q96RT1	P35499
PDB IDs		1MFG 1MFL 1N7T 2H3L 2QBW 3CH8 6Q0M 6Q0N 6Q0U 6UBG 6UBH	6AGF 6MBA 6MC9
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?